We are monitoring the impact of COVID-19 on Asia Pacific Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5075
Share on
Share on

APAC Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Analysis on Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5075
Pages: 145

The size of the Asia Pacific Gastroparesis Drugs market was around USD 1.10 Billion in 2021. It is expected to grow at a CAGR of 5.5% to reach USD 1.43 billion by 2026. It captures 20% of the global market.

Y-O-Y rise in the incidence rate of diabetes population, an increase in the number of surgical procedures, and an increase in the geriatric population in the APAC region are primarily fueling the growth rate of the APAC gastroparesis drugs market. In addition, continuous adoption of gastroparesis treatments is another factor accelerating the market's growth. Furthermore, Prokinetics drug is expected to aid in developing the gastroparesis drug market by increasing the frequency of contractions and improving gastrointestinal motility.

Furthermore, the rising prevalence of diabetic Mellitus in the Asia Pacific is driving up demand for diagnostic and treatment, and diabetes is a prominent cause of gastroparesis, propelling the gastroparesis medicine market forward. One of the other key factors is that gastroparesis is on the rise, as this is a highly prevalent type of gastroparesis with no known etiology and symptoms of vomiting, nausea, upper abdominal pain. Dietary changes, antiemetic medicine therapy, prokinetics medication, and symptoms modulators can all help to alleviate these symptoms.

It impairs regular digestion, induces vomiting, and causes blood sugar and nutrition issues, and gastroparesis is treated with various pharmaceuticals and treatments, including reglan, erythromycin, antiemetics, and others. This boosts demand for these treatments and, to some extent, the overall market.

However, side effects from gastroparesis medications, a lengthy regulatory process for therapeutic approval, and difficulties in diagnosing gastroparesis may impede the market. The lack of scientific data on the improvement delivered by prescription medications and the end of clinical trials further impose a negative impact on the gastroparesis drugs market in the APAC region.

This research report on the Asia Pacific Gastroparesis Drugs market has been segmented and sub-segmented into the following categories.

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, Asia Pacific is the fastest-growing market and is anticipated to remain in the forecast period. Emerging economies of India and China are spearheading this growth spurt. According to the Centers for Disease Control and Prevention, over 84 million Americans had prediabetes in 2019, resulting in a high prevalence of gastroparesis and regionally driving the gastroparesis medicine market.  Additionally, rising healthcare expenditures, an increase in the number of hospitals, and the presence of well-established healthcare infrastructure are also contributing to the overall regional market's growth.

Many market participants find the Asia-Pacific region to be a lucrative prospect, as nations such as India have a high prevalence rate of diabetes, which leads to gastroparesis conditions and will contribute to the gastroparesis medicine market. Furthermore, during the forecast period, a surge in demand for user-friendly medicine development, increased healthcare infrastructure, and creative marketing initiatives by leading vendors in growing nations such as India, China, and Japan are projected to present profitable prospects for market expansion.

KEY MARKET PLAYERS:

Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma is a few of the prominent companies in the gastroparesis drugs market in the APAC region.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 China                           

               6.3 India                            

               6.4 Japan                           

               6.5 South Korea               

               6.6 Australia                     

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  2. Asia Pacific Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia Pacific Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia Pacific Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia Pacific Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  6. Asia Pacific Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia Pacific Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia Pacific Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia Pacific Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  11. Asia Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia Pacific Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia Pacific Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia Pacific E-commerce Market, By Region, From 2021 to 2026 (USD Billion)
  15. Japan Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  16. Japan Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  17. Japan Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  18. China Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  19. China Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. China Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  21. India Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  22. India Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  23. India Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  24. Australia Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  25. Australia Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  26. Australia Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  27. South Korea Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  28. South Korea Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  29. South Korea Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample